Molecular Glues for Neurodegeneration: Mechanistic Insights and Clinical Implications

Abstract

Molecular glues represent a transformative class of small molecules that induce targeted protein degradation, offering innovative therapeutic strategies for neurodegenerative diseases. By promoting interactions between disease-associated proteins and E3 ubiquitin ligases, these compounds facilitate selective proteasomal degradation of pathogenic substrates. This review synthesizes current evidence on molecular glues in the context of neurodegeneration, elucidating their mechanisms, clinical relevance, and implications for future practice. Emphasis is placed on disease burden, pathophysiology, diagnostic challenges, and emerging therapies, providing healthcare professionals with up-to-date insights for clinical application.

Introduction

Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD), are characterized by progressive neuronal loss and accumulation of misfolded proteins. Despite advances in symptomatic management, disease-modifying therapies remain elusive. Molecular glues—small molecules that modulate protein-protein interactions to promote selective protein degradation—have emerged as a promising therapeutic modality. This article reviews the scientific rationale, clinical evidence, and future prospects for molecular glues in neurodegeneration, aiming to equip clinicians and researchers with comprehensive, guideline-informed knowledge.

Epidemiology / Disease Burden

Neurodegenerative diseases collectively impose a substantial global burden, with prevalence and incidence rising due to population aging. Alzheimer’s disease affects over 50 million people worldwide, with projections surpassing 150 million by 2050. Parkinson’s disease is the second most prevalent, with over 10 million cases globally. ALS and HD, while less common, are associated with significant morbidity and mortality. The economic impact is profound, with direct healthcare costs and loss of productivity estimated in the hundreds of billions annually. The lack of curative therapies underscores the urgency for novel, mechanism-based interventions such as molecular glues.

Pathophysiology

The hallmark of neurodegeneration is the aberrant accumulation of misfolded, aggregation-prone proteins—amyloid-beta and tau in AD, alpha-synuclein in PD, TDP-43 and SOD1 in ALS, and mutant huntingtin in HD. These aggregates disrupt cellular homeostasis, impair proteostasis, and trigger neuroinflammation, mitochondrial dysfunction, and synaptic loss. The ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathways are central to protein quality control but become overwhelmed or dysfunctional in disease states. Molecular glues hijack the cellular UPS by promoting neosubstrate recruitment to E3 ubiquitin ligases, leading to polyubiquitination and proteasomal degradation of pathogenic proteins. This mechanistic innovation offers disease-modifying potential by directly targeting the root cause of neurodegeneration.

Risk Factors

Risk factors for neurodegeneration are multifactorial, encompassing genetic predispositions (e.g., mutations in APP, PSEN1/2, SNCA, LRRK2, SOD1, HTT), aging, environmental exposures, vascular comorbidities, and lifestyle influences. Accumulating evidence implicates impaired proteostasis and defective protein clearance as convergent risk mechanisms. Familial forms often exhibit earlier onset and more aggressive progression, while sporadic cases are influenced by polygenic and environmental factors. Molecular glues, by targeting both genetic and sporadic forms through a shared pathogenic pathway, hold promise for broad clinical applicability.

Clinical Features

Clinical manifestations vary by disease but share overlapping features of cognitive decline, behavioral changes, motor dysfunction, and progressive disability. AD presents with insidious memory loss, executive dysfunction, and neuropsychiatric syndromes. PD is characterized by bradykinesia, rigidity, tremor, and non-motor symptoms. ALS features progressive muscle weakness, spasticity, and respiratory compromise, while HD presents with chorea, psychiatric symptoms, and cognitive impairment. Early recognition is critical, yet diagnosis is often delayed due to heterogeneity and overlap with other neurological conditions.

Diagnosis

Diagnosis relies on clinical assessment, neuroimaging, and biomarker evaluation. MRI and PET imaging reveal atrophy, hypometabolism, or protein aggregation patterns. CSF and plasma biomarkers such as amyloid-beta, tau, phosphorylated tau, and neurofilament light chain support early detection and disease monitoring. Genetic testing is indicated in familial cases. Despite advances, definitive diagnosis frequently occurs late in the disease course, limiting the window for intervention. The advent of molecular glues necessitates development of companion diagnostics to identify patients most likely to benefit from targeted degradation therapies.

Treatment & Management

Current management is largely symptomatic, utilizing cholinesterase inhibitors, NMDA receptor antagonists, dopaminergic agents, and supportive therapies. Disease-modifying strategies have been limited by failure to adequately clear pathogenic proteins or halt neurodegeneration. Molecular glues offer a paradigm shift by targeting the pathogenic substrate for degradation, potentially modifying disease progression. Integrating molecular glue therapy into management requires multidisciplinary approaches, patient selection, and monitoring of therapeutic response and adverse effects.

Recent Advances / Emerging Therapies

Molecular glues have gained prominence with the success of thalidomide analogs in hematologic malignancies. In neurodegeneration, preclinical studies have identified candidate glues targeting tau, alpha-synuclein, and TDP-43. Notably, targeted protein degradation platforms are rapidly advancing, leveraging high-throughput screening and proteomics to identify novel glue compounds. Several agents are entering early-phase clinical trials, with encouraging data on substrate specificity, blood-brain barrier penetration, and safety profiles. Ongoing research aims to optimize selectivity, minimize off-target effects, and define pharmacodynamic biomarkers.

Guideline Recommendations

While formal guidelines for molecular glue use in neurodegeneration are pending, expert consensus emphasizes the importance of rigorous clinical validation, patient stratification, and real-world safety monitoring. Recommendations include integration within clinical trial networks, adoption of standardized outcome measures, and collaboration with regulatory agencies to expedite development and approval. Multidisciplinary care teams should be educated on emerging modalities and potential adverse event profiles, ensuring informed clinical decision-making as molecular glues transition from bench to bedside.

Conclusion

Molecular glues represent a novel and promising therapeutic strategy for neurodegenerative diseases by leveraging targeted protein degradation. Early evidence suggests potential for disease modification, transcending limitations of current symptomatic therapies. Ongoing research, clinical trials, and guideline development will define their place in practice. As the molecular understanding of neurodegeneration deepens, molecular glues may become a cornerstone in precision neurology, offering hope for patients facing these devastating disorders.